drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous tumor-infiltrating lymphocytes (TILs) expanded/activated ex vivo and reinfused as cellular immunotherapy targeting patient-specific tumor antigens.
nci_thesaurus_concept_id
C187659
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs LM103 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes are expanded and activated ex vivo and reinfused; they recognize patient-specific tumor antigens via endogenous TCRs and mediate cytotoxicity through perforin/granzyme release and proinflammatory cytokines (e.g., IFN-gamma), leading to targeted tumor cell killing.
drug_name
LM103
nct_id_drug_ref
NCT05941936